GnRH analog
Phase 2Small molecule
GnRH analog is one of 32 small molecule programs targeting Embryo. It is currently in Phase 2.
2
Indications
5
Total Trials
3
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
AAA817
NovartisPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
HC-1119
HHinova Pharmaceuticals Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
GnRH analog
MMemorial Sloan Kettering Cancer Center
Phase 2
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Embryo1 trial
Adenomyosis1 trial
Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
Active, not recruiting·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 4·NCT03421639·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GnRH analog. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details